关键词 德喜曲妥珠单抗 疟原虫 ENPP1靶点 蛋白 免疫 肝炎病毒 炎症小体 人源化单克隆抗体 依库珠单抗 #今日行业热点#①The Lancet Oncology:Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study 临床研究:抗HER2抗体药物偶联物(ADC)德喜曲妥珠单抗(Trastuzumab deruxtecan,T-DXd)在美国和欧洲HER2阳性晚期胃癌或胃食管结合部癌患者中的应用效果进展:接受DESTINY-Gastric02方案的受试者的单组、Ⅱ期研究的主要和更新数据分析 DOI: 10.1016/S1470-2045(23)00215-2 ②The Lancet Infectious Diseases:Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial 临床试验:新型抗疟药物Ganaplacide (KAF156)联合抗疟活性分子Lumefantrine (苯芴醇) 用于单纯性恶性疟原虫疟疾的一项开放标签、多中心、平行组、随机、对照、Ⅱ期试验 DOI: 10.1016/S1473-3099(23)00209-8 ③Clinical Cancer Research:ENPP1 Immunobiology as a Therapeutic Target 综述:诱导免疫重构和利用STING通路的独特靶点ENPP1 DOI: 10.1158/1078-0432.CCR-22-1681 ④Molecular Therapy-Nucleic Acids:Mechanisms of NAT10 as ac4C writer in diseases 综述:n -乙酰基转移酶样蛋白10(NAT10)在疾病中的作用机制和作为潜在靶点的临床应用 DOI: 10.1016/j.omtn.2023.03.023 ⑤PNAS:Polyvalent immunization elicits a synergistic broadly neutralizing immune response to hypervariable region 1 variants of hepatitis C virus 多价免疫可引起对丙型肝炎病毒(HCV)高变区1(HVR1)变异体的协同广泛中和免疫应答 DOI: 10.1073/pnas.2220294120 ⑥Discover Oncology:Possible therapeutic targets for NLRP3 inflammasome-induced breast cancer 综述:炎症小体NLRP3在三阴性乳腺癌(TNBC)中的作用及利用NLRP3炎症小体靶向乳腺癌的潜在策略 DOI: DOI: 10.1007/s12672-023-00701-7 ⑦靶向人白介素-11(IL-11)的人源化单克隆抗体9MW3811针对特发性肺纤维化的临床试验申请已获得FDA批准 ⑧针对T细胞免疫球蛋白及黏蛋白分子-3(TIM-3)的人源化IgG1变体单克隆抗体BGB-A425获批临床,拟用于复发性或转移性头颈部鳞状细胞癌 ⑨C5补体抑制剂依库珠单抗(Eculizumab)获国家药监局批准第三项新适应症,用于成人抗乙酰胆碱受体(AChR)抗体阳性的难治性全身型重症肌无力(gMG) ⑩重组抗B7S1的阻断性人源化IgG4单克隆抗体XKH002临床试验申请(IND)获得中国NMPA批准,拟开发用于晚期实体瘤 科学探索的世界充满挑战,AtaGenix致敬每一位拓荒者,更致力于成为您信赖的合作伙伴! |
|